
ZURA
Zura Bio Stock Jumps 19.9% on Third-Quarter Results and Trial Timing Update
The company reported a wider third-quarter net loss and said its TibuSHIELD data remains on track for the fourth quarter of 2026.
Zura Bio Ltd · Nasdaq · Biological Products, (No Diagnostic Substances)

The company reported a wider third-quarter net loss and said its TibuSHIELD data remains on track for the fourth quarter of 2026.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedZura Bio Reports Q3 2026 Net Loss of $25.8 million, $0.20 per Share, With $187.7 million Cash Through 2028
Regulation FD disclosure · Financial statements and exhibits
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits